May 9, 2024Open Access

Figure S2 from ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts

View Full Paper

Ask AI

Bookmark

Abstract

Drug tolerant residual tumors exhibit variable levels of proliferation and low levels of apoptosis. IHC Quantification and additional IHC results to profile cell proliferation.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hu et al. (2024) studied this question.

synapsesocial.com/papers/68e6aeb0b6db643587630781 https://doi.org/10.1158/0008-5472.25785284

View Full Paper

Ask AI

Bookmark

Abstract

Drug tolerant residual tumors exhibit variable levels of proliferation and low levels of apoptosis. IHC Quantification and additional IHC results to profile cell proliferation.

Figure S2 from ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts

Abstract

Discussion

Cite This Study

Figure S2 from ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts

Abstract

Discussion

Cite This Study

Keep reading

Keep reading